首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents
Authors:Dragovich Peter S  Blazel Julie K  Ellis David A  Han Qing  Kamran Ruhi  Kissinger Charles R  LeBrun Laurie A  Li Lian-Sheng  Murphy Douglas E  Noble Michael  Patel Rupal A  Ruebsam Frank  Sergeeva Maria V  Shah Amit M  Showalter Richard E  Tran Chinh V  Tsan Mei  Webber Stephen E  Kirkovsky Leo  Zhou Yuefen
Institution:Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA. pdragovich@anadyspharma.com
Abstract:The synthesis of 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones bearing 6-amino substituents as potent inhibitors of the HCV RNA-dependent RNA polymerase (NS5B) is described. Several of these agents also display potent antiviral activity in cell culture experiments (EC(50)<0.10 microM). In vitro DMPK data (microsome t(1/2), Caco-2 P(app)) for many of the compounds are also disclosed, and a crystal structure of a representative inhibitor complexed with the NS5B protein is discussed.
Keywords:
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号